Inflammatory conditions dictate the effect of mesenchymal stem or stromal cells on B cell function by Luk, F. (Franka) et al.
August 2017 | Volume 8 | Article 10421
Original research
published: 28 August 2017
doi: 10.3389/fimmu.2017.01042
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Song Guo Zheng, 
Penn State Milton S. Hershey 
Medical Center, United States
Reviewed by: 
Zhibin Chen, 
University of Miami, 
United States  
Jianbo Sun, 
Sun Yat-sen University, China
*Correspondence:
Marcella Franquesa  
mfranquesa@igtp.cat
Specialty section: 
This article was submitted to 
Immunological Tolerance 
and Regulation, 
a section of the journal 
Frontiers in Immunology
Received: 31 January 2017
Accepted: 11 August 2017
Published: 28 August 2017
Citation: 
Luk F, Carreras-Planella L, 
Korevaar SS, de Witte SFH, 
Borràs FE, Betjes MGH, Baan CC, 
Hoogduijn MJ and Franquesa M 
(2017) Inflammatory Conditions 
Dictate the Effect of Mesenchymal 
Stem or Stromal Cells 
on B Cell Function. 
Front. Immunol. 8:1042. 
doi: 10.3389/fimmu.2017.01042
inflammatory conditions Dictate  
the effect of Mesenchymal stem  
or stromal cells on B cell Function
Franka Luk1, Laura Carreras-Planella2,3, Sander S. Korevaar1, Samantha F. H. de Witte1, 
Francesc E. Borràs 2,3, Michiel G. H. Betjes1, Carla C. Baan1, Martin J. Hoogduijn1 and 
Marcella Franquesa1,2*
1 Nephrology and Transplantation, Department of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, 
Netherlands, 2 REMAR Group and Nephrology Service, Germans Trias i Pujol Health Science Institute & University Hospital, 
Badalona, Spain, 3 Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona,  
Barcelona, Spain
The immunomodulatory capacity of mesenchymal stem or stromal cells (MSC) makes 
them a promising tool for treatment of immune disease and organ transplantation. The 
effects of MSC on B cells are characterized by an abrogation of plasmablast formation 
and induction of regulatory B cells (Bregs). It is, however, unknown how MSC interact 
with B cells under inflammatory conditions. In this study, adipose tissue-derived MSC 
were pretreated with 50  ng/ml IFN-γ for 96  h (MSC–IFN-γ) to simulate inflammatory 
conditions. Mature B cells were obtained from spleens by CD43− selection. B cells were 
co-cultured with MSC and stimulated with anti-IgM, anti-CD40, and IL-2; and after 
7 days, B cell proliferation, phenotype, Immunoglobulin-G (IgG), and IL-10 production 
were analyzed. MSC did not inhibit B cell proliferation but increased the percentage of 
CD38high CD24high B cells (Bregs) and IL-10 production, while MSC–IFN-γ significantly 
reduced B cell proliferation and inhibited IgG production by B cells in a more potent fash-
ion but did not induce Bregs or IL-10 production. Both MSC and MSC–IFN-γ required 
proximity to target cells and being metabolically active to exert their effects. Indoleamine 
2,3 dioxygenase expression was highly induced in MSC–IFN-γ and was responsible 
of the anti-proliferative and Breg reduction since addition of tryptophan (TRP) restored 
MSC properties. Immunological conditions dictate the effect of MSC on B cell function. 
Under immunological quiescent conditions, MSC stimulate Breg induction; whereas, 
under inflammatory conditions, MSC inhibit B cell proliferation and maturation through 
depletion of TRP. This knowledge is useful for customizing MSC therapy for specific 
purposes by appropriate pretreatment of MSC.
Keywords: B  cell, immunomodulation, mesenchymal stem cell, plasmablast, regulatory B  cell, indoleamine 
2,3-dioxygenase
inTrODUcTiOn
B  cells contribute to immunological diseases in various ways by production of auto-antibodies, 
presentation of auto-antigen, and secretion of inflammatory cytokines. In the context of post solid 
organ transplantation, B cells mediate humoral rejection by the production of donor-specific human 
leukocyte antigen (HLA) antibodies (DSAs) and provide co-stimulatory signals to T cells (1, 2). 
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On the other hand, a population of regulatory B cells (Bregs) has 
been described that can regulate immune responses mainly via 
the secretion of IL-10 (3, 4). Bregs have been shown to be involved 
in suppressing autoimmune reactions as well as in maintaining 
transplant tolerance (5, 6). Current treatments for B cell-medi-
ated disease are mainly based on global B cell depletion, thereby 
eliminating pathogenic B  cells as well as Breg subsets. A more 
refined modulation of B cell activity could prove beneficial for 
patient treatment.
Mesenchymal stem or stromal cells have potent immunomod-
ulatory properties and target the proliferation and differentiation 
of a variety of immune cells (7). The effect of MSC on T  cells 
has been extensively studied but also regulation of natural killer 
cells (8), macrophages (9), dendritic cells (10), and more recently 
B cells by MSC has drawn attention. Previously, we have shown 
that MSC can abrogate plasmablast formation and induce IL-10+ 
and CD19+ CD38high CD24high B  cells (11), which are the two 
main signatures to define Bregs (12). However, it appears that the 
nature of the immunosuppressive and anti-proliferative effects 
of MSC on lymphocytes is dependent on the inflammatory 
microenvironment (13–16). In particular, IFN-γ has a prominent 
role in potentiating the anti-proliferative capacity of MSC via the 
induction of indoleamine 2,3-dioxygenase (IDO) activity (17) 
and contact dependent mechanisms of action (18, 19). Priming of 
MSC with inflammatory factors is likely to occur in vivo as MSC-
treated patients often suffer from acute or chronic inflammatory 
diseases. MSC infused in patients might encounter an inflamma-
tory environment that could influence the immunomodulatory 
effect of MSC.
We previously showed that B  cell proliferation is increased 
when B cells are stimulated by an anti-CD40 + anti-IgM + IL-2 
cocktail as well as with activated T cells. MSC reduced B cell pro-
liferation induced by stimulated T cells but not by the cocktail in 
the absence of T cells (11). In our previous work, we hypothesized 
that the anti-proliferative effect of MSC on B cells in the presence 
of activated T cells was due to the secretion of IFN-γ by activated 
T cells and the subsequent activation of MSC. In this study, we 
examined how IFN-γ affected the immunomodulatory role of 
MSC on B cells by comparing the effects of MSC and IFN-γ treated 
MSC on B cell proliferation and differentiation into plasmablasts 
or IL-10 producing Bregs.
MaTerials anD MeThODs
isolation and culture of human 
subcutaneous adipose Tissue Msc
Subcutaneous adipose tissue from healthy human donors that 
became available as a waste product during kidney donation 
procedures was collected after obtaining written informed 
consent as approved by the Medical Ethical Committee of the 
Erasmus University Medical Centre Rotterdam (protocol no. 
MEC-2006-190). The tissue was collected in minimum essential 
medium-α (MEM-α) (Sigma Aldrich, St. Louis, MO, USA) sup-
plemented with penicillin (100 IU/ml), streptomycin (100 mg/ml) 
(1% P/S; Lonza, Verviers, Belgium), and 2  mM L-glutamine 
(Lonza) and stored at 4°C for 3–16  h. MSC were isolated as 
described previously (20). Briefly, adipose tissue was mechani-
cally disrupted and digested enzymatically with 0.5 mg/mL col-
lagenase type IV (Life Technologies, Paisley, UK) in RPMI 1640 
Medium with glutaMAX (Life Technologies) for 30 min at 37°C 
under continuous shaking. Cultures were kept at 37°C, 5% CO2, 
and 95% humidity and refreshed weekly with MEM-α with 1% 
P/S, and 15% heat-inactivated fetal bovine serum (FBS; Lonza). 
At 90% confluence, adherent cells were removed from culture 
flasks by incubation in 0.05% trypsin-EDTA (Life Technologies, 
Bleiswijk, The Netherlands) at 37°C and cells used for experi-
ments or frozen at −150°C until further use. MSC were used 
for experiments between passages 2 and 5 and their phenotypic 
markers and osteogenic and adipogenic potential were tested as 
described before (21). MSC from 19 different donors were used 
in the experiments.
stimulation of Msc
Mesenchymal stem or stromal cells were pretreated for 4 days 
with IFN-γ (50  ng/ml; Life technologies). For co-culture 
experiments, MSC were washed with phosphate buffered saline 
(PBS) and detached by incubation with 0.05% trypsin-EDTA 
before seeding them in 96 well-plates in Iscove’s Modified 
Dulbecco’s Medium (IMDM, Lonza) with 10% heat inactivated 
FBS. Phenotypical characteristics of MSC before and after 
IFN-γ were assessed measuring several markers on their sur-
face: CD13-PeCy7 (clone L138), CD31-V450 (clone WM59), 
CD45-APC-H7 (clone 2D1), HLA-ABC-APC (clone G46-2.6), 
HLA-DR PerCP (clone L243) and CD73-PE (clone AD2; all BD 
Biosciences), CD90-APC (clone Thy-1A1), and CD105-FITC 
(clone 166707; all R&D Systems, Minneapolis, MN, USA) and 
PD-L1 PE (clone B7-H1; Biolegend, San Diego, CA, USA) by 
Flow Cytometry and optical microscopy morphology (Figure S1 
in Supplementary Material).
iDO activity Measurement
The activity of IDO was determined by the measurement 
of L-kynurenine in the supernatant of four MSC cultures as 
described previously (22). Briefly, MSC were seeded at a density of 
100,000 cells/well in a 6 wells plate and cultured for 4 days with or 
without 50 ng/mL IFN-γ. 30% trichloroacetic acid was added to 
the supernatant in a 1:3 ratio. Samples were incubated for 30 min 
at 50°C and spun down at 12,000 rpm for 5 min. Samples were 
plated in a 96 wells flat bottom plate and diluted 1:1 in Ehrlich 
reagent [200 mg 4-dimethylaminobenzaldehyde (Sigma-Aldrich, 
St. Louis, MO, USA) in 10 ml of glacial acetic acid]. Absorbance 
was read at 490 nm using a Wallac Victor2 1420 multilabel plate 
reader (Perkin Elmer, Waltham, MA, USA).
isolation of B cells from spleens
Spleens were obtained from post-mortal kidney donors (Erasmus 
MC Hospital, Rotterdam) and anonymously used for research 
purposes as described in article 13 of The Netherlands law of 
organ donation (Wet op Orgaandonatie, WOD). All samples and 
data were analyzed anonymously. Spleens were mechanically 
disrupted and filtered through a 70-µm cell strainer (Greiner 
Bio-one, Alphen a/d Rijn, The Netherlands) to obtain a single-
cell suspension. Mononuclear cells, isolated using Ficoll-Paque 
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(Amersham Pharmacia Biotech, Uppsala, Sweden) density gradi-
ent, were stored at −150°C until use. Upon thawing, quiescent 
B  cells were isolated by negative selection using anti-CD43-
magnetic beads (Miltenyi Biotec GmbH, Bergisch Gladbach, 
Germany) (23). Purity was determined by flow cytometry (FACS 
Canto II). Typically, cell suspensions consisted of >98% pure 
CD19+ B cells. B cells from spleens from 12 different donors were 
used it the experiments.
B cell stimulation
B  cells were co-cultured in IMDM-10%FBS with a cocktail 
to mimic antigen and T  cell help: 10  mg/ml F(ab)2 anti-IgM 
(Jackson, ImmunoResearch laboratories, Inc., West Grove, PA, 
USA), 103 IU IL-2 (Proleukin, Prometheus laboratories Inc., San 
Diego, CA, USA), and 5 mg/ml anti-CD40 agonistic monoclonal 
antibody (Bioceros, Utrecht, The Netherlands). In some of the 
experiments, 200  µM tryptophan (TRP, l-tryptophan, Sigma-
Aldrich) was added to the stimulation cocktail to counteract the 
activity of IDO.
Transwell (TW) cultures
24-wells plates with 0.4 μm pore polycarbonate membrane inserts 
(Costar, Corning, Kennebunk, ME, USA) were used for the TW 
cultures. MSC were seeded on the membrane of the inserts and 
B cells were added to the lower chamber at a ratio MSC:B cells 
1:5. After 7 days, inserts were removed; and B cells from the lower 
chamber were collected for further analysis and B  cell subsets 
characterization.
heat inactivated Msc
To study the effect of cell surface molecules but not the secreted fac-
tors, MSC were inactivated as previously described (24). Shortly, 
MSC were heated in suspension in PBS in parafilm-sealed tubes 
by 30 min incubation at 50°C in a temperature-regulated water 
bath. The inactivated cells were then washed and counted and 
used for further experiments.
B cell subset characterization
B  cells were labeled by incubation with 5,6-carboxy- 
succinimidyl-fluoresceine-ester (CFSE) (Molecular Probes 
Invitrogen, Karlsruhe, Germany) for 10 min at 37°C.
After 7 days, B cells were collected and processed for flow cyto-
metric analysis (FACS Canto II, Diva Software, BD Biosciences, 
San Jose, CA, USA), and supernatants were stored at −80°C 
for cytokine and Immunoglobulin-G (IgG) determination. The 
antibodies used for flow cytometry phenotyping were as follows: 
CD27-PE-Cy7 (clone 0323), CD38-PE (clone HB7), CD19-BV512 
(clone HIB19) and CD24-APC (clone SN3 A5-2H1D) (eBiosci-
ence, San Diego, CA, USA), IL-10-Bv421 (Clone Jes3-9D7, 
Biolegend), and Via Probe for determination of cell viability 
(BD Biosciences, San Jose, CA, USA). After 7  days, prolifera-
tion of B cells was assessed by measuring CFSE dye dilution on 
a FACSCanto II flow cytometer (BD Biosciences). 12  h before 
harvesting the cells, Monensin (Golgi Stop, BD Biosciences) was 
added to the wells and the intracellular staining was performed 
without restimulation using Intrastain kit (Dako, Denmark).
Measurement of cytokine secretion
Supernatants from MSC-B cell co-cultures kept at −80°C were 
thawed and used for measurement of cytokine levels. IL-10 was 
quantified using a Milliplex kit (Merck Millipore, Amsterdam, 
The Netherlands) according to manufacturer’s instructions. 
Human cytokine standards were provided by the kit and a 
standard curve was prepared from 10,000 to 3.2 pg/ml. Samples 
and standards mixed with antibody-coated magnetic beads were 
incubated overnight in a 96-well plate at 4°C under continuous 
agitation. Plates were washed and incubated with detection 
antibodies for 1  h. Finally, plates were washed and incubated 
with streptavidin-phycoerythrin for 30  min. The samples were 
measured on a Luminex 100/200 cytometer (Luminex, Austin, 
TX, USA) using Xponent software.
igg elisa
Plates were coated with goat anti human Ig-UNLB (Southern 
Biotechnology Associates; Birmingham, AL, USA). Plates were 
washed with PBS 0.05% Tween and blocked with PBS 5% FBS 
for 2 h. Diluted samples and standard IgG (Sigma-Aldrich) were 
added to the plate and incubated for 90  min. IgG-HRP (My 
Biosource; San Diego, CA, USA) was used as a conjugate and 
3,3,5,5-tetramethylbenzidine (TMB) was used to visualize bound 
IgG. Absorbance was read at 595 nm using a Wallac Victor2 1420 
multilabel plate reader (Perkin Elmer, Waltham, MA, USA).
rna expression Quantification
After 7 days of co-culture, B cells were recovered, pelleted in PBS–
DEPC and snap frozen. RNA was isolated and 500 ng was used 
for cDNA synthesis as described previously (25). Gene expression 
was determined by real-time RT-PCR using universal PCR mas-
ter mix (Life Technologies) and an assay-on-demand for IL-10 
(Hs00174086.m1) (Applied Biosystems, Foster City, CA, USA) 
and analyzed on an ABI PRISM 7700 sequence detector (Applied 
Biosystems). Data are expressed as relative copy number of the 
PCR products with respect to the housekeeping gene GAPDH.
statistical analysis
Data are expressed as means ± SEM. Significant differences within 
groups were calculated using repeated measures non-parametric 
analysis of variance (ANOVA: Friedman test) with Dunnett’s 
posttest performed by GraphPad Prism 5 software (GraphPad 
Software, San Diego, CA, USA). P values were indicated as * for 
P < 0.05; ** for P < 0.01; and *** for P < 0.001.
resUlTs
iFn-γ-Pretreated Msc inhibit  
B cell Proliferation
Previously, we showed that the inhibition of B cell proliferation 
by MSC was dependent on the presence of T  cells (11). We 
hypothesized that MSC needed to be activated by IFN-γ secreted 
by T cells to mediate their anti-proliferative effects on B cells.
Here, we analyzed the anti-proliferative capacity of MSC and 
IFN-γ-pretreated MSC (MSC–IFN-γ) on anti-CD40, anti-IgM, 
FigUre 1 | IFN-γ stimulated mesenchymal stem or stromal cells (MSC) reduce B cell proliferation. B cells from human splenocytes were stimulated for 7 days with 
anti-CD40, anti-IgM and IL-2 in the presence of adipose tissue-derived MSC or IFN-γ-pretreated MSC (MSC–IFN-γ). (a) Representative FACS plots of the gating 
strategy of live, naïve, and memory B cells based on intensity of CD27 expression. (B) Proliferation of B cells in the presence or absence of MSC or MSC–IFN-γ at a 
5:1 (B cell:MSC) ratio was assessed through measurement of 5,6-carboxy-succinimidyl-fluoresceine-ester (CFSE) label dilution. Representative histograms were 
shown. Gray, solid histograms represent unstimulated B cells. (c) Percentage of proliferation of B cells (left graph), naïve B cells (middle graph), and memory B cells 
(right graph). Bars indicate mean ± SEM of three experiments with three different MSC cultures and three different B cell donors.
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and IL-2 stimulated B cells using flow cytometry. After 7 days of 
co-culturing with MSC or MSC–IFN-γ, viable naïve and memory 
B cells were distinguished based on intensity of CD27 as shown 
in Figure 1A.
Co-culture of B  cells with MSC significantly increased the 
proliferation of the total B cell population (Figures 1B,C). MSC 
that were pretreated with IFN-γ did not increase the proliferation 
of B cells but, by contrast, inhibited B cell proliferation from 65 
5Luk et al. Modulation of B Cell Function by Human MSC
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to 40%. Naïve and memory B cell subsets (CD27− and CD27+, 
respectively) showed similar increases in proliferation when 
co-cultured with MSC and inhibition of proliferation when co-
cultured with MSC–IFN-γ.
These results show that MSC need to be pre-activated with 
IFN-γ to bring about their anti-proliferative effect on B cells.
iFn-γ-Pretreated Msc inhibit igg 
Production by B cells
Mesenchymal stem or stromal cells reduced IgG production by 
activated B cells (Figure 2A). Pretreatment of MSC with IFN-γ 
significantly enhanced the inhibitory effect of MSC on IgG pro-
duction. In accordance with the reduced proliferation, an even 
stronger reduction of IgG levels was measured in the supernatant 
of B cells co-cultured with MSC–IFN-γ.
iFn-γ conditioned Msc are Poor Breg 
inducers
To investigate whether MSC-induced B  cells with a regulatory 
phenotype, frequencies of CD19+ CD38high CD24high transitional 
B cells (Bregs), and IL-10 production were measured. After 7 days 
of co-culturing MSC and MSC–IFN-γ with T cell-like stimulated 
B cells, the percentage of Bregs was measured using flow cytometry 
as shown in Figure 2B. MSC significantly induced an increase of 
this subset. By contrast, IFN-γ-pretreated MSC were not able to 
induce an increase in Bregs (Figures 2B,C). In accordance with 
this, the absolute number of Bregs was significantly increased 
when MSC were co-cultured with B cells (Figure 2D).
To analyze whether the induced cells had regulatory poten-
tial, the anti-inflammatory cytokine IL-10 gene expression was 
analyzed. MSC induced a higher trend in IL-10 gene expression, 
while MSC–IFN-γ did so only to a very low extent (Figure 2E). 
In accordance with this, IL-10 protein levels were significantly 
increased in the B  cell and MSC co-cultures supernatants, 
whereas no increase in IL-10 levels was found in the supernatant 
of B cell and MSC–IFN-γ (Figure 2F). The proportion of IL-10-
producing B cells was also analyzed in the different conditions 
by intracellular staining and accordingly we identified a higher 
percentage in the co-culture with MSC (Figure 2G).
To further analyze the phenotype of the IL-10-producing 
B cells induced by MSC we performed intracellular IL-10 stain-
ing. The transitional CD38high CD24high subset showed the highest 
percentage of IL-10+ cells, although also within the naïve CD38int 
CD24int B cell subset significant numbers of IL-10-producing cells 
were found (data not shown). In absolute numbers, the largest 
proportion of IL-10-producing B cells was observed in the CD38int 
CD24int subset, which corresponds to the mature naïve subset. We 
observed that all IL-10+ B cells produced in the presence of MSC 
were CD27− (Figure 2H).
The reduction of B cell Proliferation  
by iFn-γ-Pretreated Msc requires  
close Proximity
To test whether soluble factors or cell contact-dependent mecha-
nisms are involved in the effects of MSC and MSC–IFN-γ on 
B cell proliferation and Breg induction, activated B cells were co-
cultured with MSC and MSC–IFN-γ in a TW system to prevent 
cell–cell contact as shown in Figure  3A. By preventing direct 
cell–cell contact, the stimulatory effect of MSC on B cell prolifera-
tion was abolished (Figure  3B). Moreover, a small decrease in 
memory B cell proliferation was measured when B cells were co-
cultured with MSC in a TW setting. Interestingly, prevention of 
direct cell–cell contact also abolished the anti-proliferative capac-
ity of MSC–IFN-γ both in the total B cell population and in the 
naïve and memory B cell populations (Figure 3B). In accordance 
with the lack of proliferation inhibition in co-cultures of B cells 
with MSC–IFN-γ in a TW system, levels of IgG were not affected 
by MSC and MSC–IFN-γ (Figure 3C). No Bregs were induced 
when B  cells were co-cultured with MSC and MSC–IFN-γ in 
TW system (Figure 3D), and, in correspondence, no increase in 
IL-10 levels was found (Figure 3E). These results indicate that the 
inhibition of B cell proliferation, inhibition of IgG production, 
and induction of IL-10 production by MSC is dependent on cell 
contact or at least close proximity of MSC and B cells.
The reduction of B cell Proliferation 
requires Metabolically active  
Msc–iFn-γ
To examine whether the inhibition of B cell proliferation by MSC–
IFN-γ requires merely interaction via membrane proteins or 
requires metabolically active MSC–IFN-γ, activated B cells were 
co-cultured with heat-inactivated MSC (HI-MSC) (Figure 4A). 
HI-MSC are immunophenotypically intact but release no soluble 
factors, as previously described (24). Culturing B  cells with 
HI-MSC abolishes the stimulatory effect of MSC on B cell prolif-
eration (Figure 4B) and furthermore the proliferation of B cells 
was not significantly inhibited by HI-MSC–IFN-γ (Figure 4B). 
HI-MSC and HI-MSC–IFN-γ induced an increase in Bregs but 
this increase was not linked to an increase in IL-10 production 
(Figures 4C,D). These data indicate that the inhibition of B cell 
proliferation is dependent on metabolic activity of MSC–IFN-γ. 
Furthermore, the induction of Bregs cannot be recuperated by 
inactivating MSC–IFN-γ but requires metabolically active MSC. 
Activating MSC with IFN-γ appears to overrule the Breg induc-
ing capacity of MSC.
inhibition of B cell Proliferation by iFn-γ 
stimulated Msc is largely Dependent  
on TrP catabolism by iDO
We hypothesized that the inhibition of B  cell proliferation by 
MSC is mediated by IFN-γ triggered IDO induction, leading to 
degradation and depletion of TRP. When MSC were cultured for 
4 days with IFN-γ high levels of l-kynurenine, the breakdown 
product of TRP, were detected (Figure 5A). When 200 µM TRP 
was added to B cell and MSC–IFN-γ co-cultures to counteract 
the effect of IDO activity, B cell proliferation increased from 17 
to 48% in the total B cell population, from 19 to 52% in the case 
of naïve B cell proliferation, and from 16 to 36% in the case of 
memory B cell proliferation (Figure 5B). TRP supplementation, 
furthermore, reversed the effect of MSC–IFN-γ on IgG produc-
tion by B cells (Figure 5C).
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FigUre 2 | Continued
FigUre 2 | Continued  
IFN-γ-pretreated mesenchymal stem or stromal cells (MSC) prevent immunoglobulin-G (IgG) production by B cells and regulatory B cell (Breg) formation. (a) Levels 
of IgG were measured in the supernatant of anti-CD40, anti-IgM and IL-2 stimulated B cells co-cultured with or without MSC or MSC– IFN-γ at a 5:1 (B cell:MSC) 
ratio for 7 days. (B) Representative FACS plots of the gating strategy of Bregs, identified as CD38hiCD24hi B cells, with or without MSC or MSC–IFN-γ for 7 days.  
(c) Percentage of Bregs of total B cells after culturing with or without MSC or MSC–IFN-γ for 7 days. (D) The absolute number of total B cells was counted after 
harvesting the cells from the co-cultures (left graph). The absolute number of Bregs in the culture was calculated using the percentage of Bregs measured with flow 
cytometry and the absolute number of total B cells (right graph). Both absolute counts refer to initial 100,000 B cells in culture. (e) Gene expression of IL-10 
depicted as a ratio to GAPDH. (F) Levels of IL-10 were measured in the supernatant of anti-CD40, anti-IgM, and IL-2 stimulated B cells co-cultured with or without 
MSC or MSC– IFN-γ. (g) IL-10 + B cells frequencies measured by analyzing intracellular cytokine by flow cytometry. B cells co-cultured with MSc showed the 
higher frequencies. (h) IL-10 intracellular staining of B cells co-cultured with MSC (B + MSC group). IL-10 positive B cells are plotted to show the percentage of 
transitional (CD24hi CD38hi), CD24int CD38int, and CD24hi CD38− subsets. All bars indicate mean ± SEM of three experiments with three different MSC cultures and 
three different B cell donors.
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TrP supplementation rescues Breg 
induction by iFn-γ stimulated Msc
We showed that IFN-γ-pretreated MSC were not able to induce 
an increase in Bregs. TRP supplementation to MSC–IFN-γ and 
B cell co-cultures showed a trend toward increased frequencies 
of CD38high CD24high Bregs (Figure 5D). In accordance with this, 
the levels of IL-10 in the supernatant of the MSC–IFN-γ cultures 
were significantly increased when B cell proliferation was rescued 
with TRP supplementation (Figure 5E). Stimulation of MSC and 
MSC–IFN-γ with T cell-like stimulation and TRP did not induce 
IL-10 secretion by MSC, eliminating the possibility that the IL-10 
in the stimulated cultures is secreted by MSC–IFN-γ (data not 
shown). These data indicate that the incapability of MSC–IFN-γ 
to induce Bregs is caused by TRP depletion mediated by IFN-γ 
triggered IDO activity in MSC.
DiscUssiOn
The immunomodulatory properties of MSC are under strict 
control of pro-inflammatory factors, such as IFN-γ (13). In this 
study, we show that inflammatory signals alter the effect of MSC 
on B cells. In the absence of immune activation, MSC promote 
the survival of B cells and induce the formation of Bregs, whereas 
they have little effect on B cell proliferation and IgG production 
(11). However, after pretreatment with IFN-γ, MSC inhibit B cell 
proliferation, reduce IgG production, but they also lose the 
capacity to induce Bregs (Figure 6). During immune responses, 
immune cells involved in graft rejection such as T cells, mono-
cytes, or macrophages can provide IFN-γ to MSC (26, 27). We 
previously showed that in the absence of T  cells, MSC fail to 
inhibit activated B  cell proliferation (11). Our results indicate 
that IFN-γ production by T  cells is required to activate MSC 
to dampen the proliferative response of B  cells. The decreased 
levels of IgG and Bregs found when B cells were co-cultured with 
IFN-γ-stimulated MSC are likely a consequence of the inhibited 
proliferation of B cells. These data indicate that the effects of MSC 
on B cells may be very different in situations where no T cells are 
around, such as, for instance, in patients in which T cells have 
been depleted with anti-thymocyte globulin after solid organ 
transplant rejection (28).
The interaction between MSC and B  cells has been investi-
gated in a number of studies, although study outcomes have been 
contrasting with respect to effects of MSC on B cell proliferation 
and antibody production (29). In this study, we clarified that 
the effect of MSC on B  cells depends on local immunological 
conditions. Under immunological quiescent conditions, MSC 
are supportive for B cells; they promote B cell survival and Breg 
formation. Bregs will subsequently contribute to maintenance of 
immunological homeostasis. Under inflammatory conditions, 
in our study mimicked by the addition of IFN-γ, MSC suppress 
the activity of B cells; they inhibit B cell proliferation and reduce 
antibody production. At the same time, they inhibit Bregs induc-
tion. This may seem counterintuitive, but may reflect a state in 
which all B cell activity is shut down by MSC. Our results imply 
that in vivo, resident MSC are supportive for B cells and induce 
tolerogenic B  cells under immunological quiescent conditions, 
whereas under inflammatory conditions MSC suppress humoral 
responses. For the generation of therapeutic MSC our results 
suggest that custom-made MSC can be generated with either 
B  cell suppressive properties or with B  cell homeostasis sup-
portive properties. Distinct mechanisms have been described 
to be responsible for immunomodulation by MSC. Both soluble 
factors and contact-dependent ligand–receptor interaction have 
been proposed to participate to the MSC-mediated immu-
nomodulation (30). We show that MSC effects on B cells do not 
solely depend on soluble factors as no Bregs or IL-10 production 
were induced when MSC were cultured in a TW culture system. 
Moreover, the presence of dead but phenotypically intact MSC 
(24) was not enough to induce IL-10-producing B cells, imply-
ing that modulation of B cells by MSC is mediated by an active 
metabolic process and needs close proximity of MSC and B cells.
Indoleamine 2,3-dioxygenase-mediated TRP catabolism has 
been described as an important mechanism of activated MSC 
to modulate T cell proliferation (17). We demonstrated that the 
inhibition of B cell proliferation by MSC also largely depends on 
the TRP depleting activity of IDO activity and can be recovered 
by supplementing TRP in vitro. We show that the ability of MSC 
to induce IL-10-producing B  cells was lost when MSC were 
pretreated with IFN-γ but could be recovered when TRP was 
supplemented to the culture. Thus, in the tested experimental 
conditions, MSC–IFN-γ act in a similar way to non-activated 
MSC upon TRP supplementation, indicating that IFN-γ-induced 
IDO activity plays a major role in the effect of IFN-γ-activated 
MSC on B cells.
In this study, we named the transitional B  cell subset char-
acterized by CD19+ CD24hi CD38hi as Bregs, since this is one of 
the most commonly used phenotypes for this subset of B cells in 
FigUre 3 | The reduction of B cell proliferation by IFN-γ-pretreated mesenchymal stem or stromal cells (MSC) requires close proximity. (a) B cells were stimulated 
with anti-CD40, anti-IgM, and IL-2 and cultured in direct contact with MSC or MSC– IFN-γ or in transwell (TW) system to prevent direct cell contact of the B cells 
and MSC. (B) Proliferation of B cells was assessed through measurement of 5,6-carboxy-succinimidyl-fluoresceine-ester label dilution. (c) Levels of 
immunoglobulin-G measured in the supernatant with an ELISA assay. (D) Percentage of CD24hiCD38hi regulatory B cells within CD19 + cell gate measured by flow 
cytometry. (e) Levels of IL-10 measured in the supernatant with an ELISA assay. All bars indicate mean ± SEM of three experiments with three different MSC 
cultures and three different B cell donors.
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FigUre 4 | The reduction of B cell proliferation by IFN-γ-pretreated mesenchymal stem or stromal cells (MSC) requires viable cells. (a) MSC were incubated for 
30 min at 50°C to heat inactivate the cells (HI-MSC). B cells were stimulated with anti-CD40, anti-IgM, and IL-2 and cultured for 7 days with HI-MSC or  
HI-MSC–IFN-γ. (B) Proliferation of B cells was assessed through measurement of 5,6-carboxy-succinimidyl-fluoresceine-ester label dilution. (c) Percentage of 
induced CD24hiCD38hi regulatory B cells within CD19 + cell gate measured by flow cytometry. (D) The levels of IL-10 were measured in the supernatant of B cells 
cultured in the presence of viable MSC or MSC– IFN-γ or HI-MSC or HI-MSC–IFN-γ. All bars indicate mean ± SEM of three experiments with three different MSC 
cultures and three different B cell donors.
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FigUre 5 | Inhibition of B cell proliferation by IFN-γ stimulated mesenchymal stem or stromal cells (MSC) is largely dependent on tryptophan (TRP) catabolism by 
indoleamine 2,3-dioxygenase (IDO). (a) IDO activity was measured by accumulation of l-kynurenine in MSC supernatant after 4 days culture with or without 50 ng/
mL IFN-γ. (B) anti-CD40, anti-IgM, and IL-2 stimulated B cells were co-cultured with MSC or MSC–IFN-γ for 7 days in the absence or presence of 200 µM 
tryptophan (TRP). Proliferation of CFSE labeled B cells is depicted as mean ± SEM of 3 experiments with different MSC cultures. IgG (c) and IL-10 (e) levels were 
measured in the supernatant of the cultures using ELISA. (D) Percentage of induced regulatory B cells within CD19 + cells with or without added MSC or IFN-γ in 
the presence or absence of 200 µM TRP for 7 days. All bars indicate mean ± SEM of three experiments with three different MSC cultures and three different B cell 
donors.
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FigUre 6 | Model for the interactions between adipose tissue-derived mesenchymal stem or stromal cells (MSC) and B cells in immunological quiescent and in 
inflammatory conditions. MSC have a stimulatory effect on B cell proliferation and regulatory B-cell formation in an immunological quiescent environment. Under 
inflammatory conditions, MSC break down tryptophan (TRP) through indoleamine 2,3-dioxygenase (IDO). The depletion of TRP leads to an inhibition of B cell 
proliferation and prevents regulatory B-cell formation.
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humans and we have previously proven it is consistently upregu-
lated in the presence of MSC. We further characterized this subset 
by quantification of IL-10 production as IL-10 is the most widely 
used to define Bregs function. The definition of the Breg popula-
tion is an important discussion point in our manuscript and in 
current literature. There is no unique signature that identifies the 
Breg subset and probably there are many different Breg subsets 
with different phenotypes. In our setting, we have previously 
observed that MSC increase the proportion of naïve (CD19+ 
CD27−) and transitional (CD19+ CD24high CD38high) B  cells, 
which was correlated to an increase of IL-10 gene expression and 
protein production (11). However, the intracellular IL-10 staining 
in this study reveals that there is no complete match between the 
transitional B cells immunophenotype and IL-10-producing cells, 
so further marker discovery is needed to unravel a more suitable 
signature or a master transcription factor that would allow to 
properly label Bregs. While such key markers are not discovered, 
we used both the transitional B cell immunophenotype and the 
amount of IL-10 released in the culture medium to semi-quantify 
the Breg population in this study.
Better understanding of the interaction between MSC and 
B cells under different immunological conditions is important 
for designing therapeutic approaches targeting B  cells using 
MSC. Conventional MSC therapy can potentially be used to 
induce Breg formation and thereby promote tolerance such as 
after organ transplantation. Peng et al. show that MSC therapy 
in chronic graft versus host disease patients led to increased 
number of IL-10-producing CD5+ Bregs and increased IL-10 
production by these cells (31). On the other hand, IFN-γ-
activated MSC as therapy could be beneficial in B cell-mediated 
diseases where suppression of B  cell proliferation and IgG 
production is desired.
12
Luk et al. Modulation of B Cell Function by Human MSC
Frontiers in Immunology | www.frontiersin.org August 2017 | Volume 8 | Article 1042
To summarize, we show that immunological conditions can 
dictate the effect of MSC on B cell function. MSC induce B cells 
with a regulatory phenotype but are not capable to dampen B cell 
proliferation. Under T  cell-mediated inflammatory conditions, 
MSC strongly inhibit B cell proliferation and, as a consequence, 
IgG production although they do not induce formation of Bregs. 
This shows for the first time that MSC adapt their effect on B cells 
to the inflammatory climate. In vivo this means that resident MSC 
are supportive for B cells and induce tolerogenic B cells under 
immunological quiescent conditions, whereas under inflamma-
tory conditions MSC suppress humoral responses. For therapeu-
tic MSC, this means that we can generate MSC with either B cell 
suppressive properties, or MSC that support B cell homeostasis. 
With this knowledge specific MSC therapy can be designed for 
different immune disorders or transplantation.
aUThOr cOnTriBUTiOns
FL: collection of data, data analysis and interpretation, and 
manu script writing. LC-P: collection of data, data analysis and 
interpretation, and final approval of manuscript. SK: collection of 
data, data analysis and interpretation, and final approval of manu-
script. SW: collection of data, data analysis and interpretation, and 
final approval of manuscript. FB: final approval of manuscript. 
MB and CB: data analysis and interpretation, and final approval 
of manuscript. MH: conception and design, data analysis and 
interpretation, and manuscript writing. MF: conception and 
design, collection of data, data analysis and interpretation, and 
manuscript writing.
acKnOWleDgMenTs
M. Franquesa is in receipt of a Beatriu de Pinós-B grant (2014BP 
B00118).
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found 
online at http://journal.frontiersin.org/article/10.3389/fimmu. 
2017.01042/full#supplementary-material.
FigUre s1 | Characterization of MSC before and after culturing with IFN-γ. 
MSC were cultured for 4 days with IFN-γ (50 ng/ml). (a) Bright-field image of 
cultured MSC shows characteristic MSC morphology before and after culturing 
with IFN-γ. (B) The presence of CD13, CD73, CD90, CD105, HLA-ABC, 
HLA-DR, and PD-L1 and absence of CD45 and CD31 cell surface markers 
measured on MSC before (solid line) and after culturing with IFN-γ (dotted line). 
Gray, solid histograms represent unstained MSC.
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